A study to find out how healthy people tolerate a new drug called S221237.

2024-519381-53-00 Protocol CL1-221237-002 Human pharmacology (Phase I) - First administration to humans Ended

Start 4 Oct 2022 · End 14 Oct 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CL1-221237-002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 103
Countries 1
Sites 1

Parkinson disease (PD)

Key facts

Sponsor
Institut De Recherches Internationales Servier IRIS
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
4 Oct 2022 → 14 Oct 2024
Decision date (initial)
2024-11-13
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-519381-53-00
EudraCT number
2022-001526-30

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Parkinson disease (PD)

VersionLevelCodeTermSystem organ class
20.0 PT 10061536 Parkinson's disease 100000004852
20.0 SOC 10029205 Nervous system disorders 8

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut De Recherches Internationales Servier IRIS

Sponsor organisation
Institut De Recherches Internationales Servier IRIS
Address
22 Route 128
City
Gif Sur Yvette
Postcode
91190
Country
France

Scientific contact point

Organisation
Institut De Recherches Internationales Servier IRIS
Contact name
Clinical Studies Department

Public contact point

Organisation
Institut De Recherches Internationales Servier IRIS
Contact name
Clinical Studies Department

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 103 1
Rest of world 0

Investigational sites

France

1 site · Ended
Eurofins Optimed
Clinical unit, 1 Rue Des Essarts, 38610, Gieres

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2022-10-04 2024-10-14 2022-10-04 2024-09-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-07 France Acceptable
2024-11-12
2024-11-13